<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1322">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04920786</url>
  </required_header>
  <id_info>
    <org_study_id>TB006HV1101</org_study_id>
    <nct_id>NCT04920786</nct_id>
  </id_info>
  <brief_title>Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects</brief_title>
  <acronym>TB006SAD</acronym>
  <official_title>A Phase 1 Double-blind, Randomized, Single Dose, Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TrueBinding, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TrueBinding, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single dose, dose-escalation study to assess the safety, tolerability,&#xD;
      pharmacokinetics and pharmacodynamics of TB006, a monoclonal antibody that will be studied as&#xD;
      a disease modifying treatment for Alzheimer's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The TB006 nonclinical pharmacology program establishes its potential as a therapeutic agent&#xD;
      for AD. Overall, the data suggest the potential for beneficial therapeutic effects of TB006&#xD;
      in addressing underlying pathology and ameliorating the course of AD. The preclinical safety&#xD;
      profile of TB006 further supports the clinical investigation of TB006. This is a Phase 1 SAD&#xD;
      study in healthy adult subjects. The study will evaluate the safety, tolerability, and PK of&#xD;
      single doses of TB006, administered as an IV infusion over 1 hour.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Six dose groups are planned: 5 dose levels of TB006 in healthy subjects and 1 ethno-bridging group in healthy subjects of Chinese descent.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects and rate of treatment-emergent adverse events, graded by CTCAE Version 5.0, by dose group and all active treatment vs. placebo</measure>
    <time_frame>Day1-Day 75</time_frame>
    <description>To measure the incidence of AEs and SAEs, clinical laboratory parameters, and vital signs until Day 75 after dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the single-dose PK profile of TB006 in healthy adult subjects</measure>
    <time_frame>Through day 75</time_frame>
    <description>PK parameters derived by noncompartmental analysis using the TB006 plasma concentration-time data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the MTD of single doses of TB006 in healthy adult subjects</measure>
    <time_frame>Through day 75</time_frame>
    <description>Dose-response relationship of AEs and SAEs, and other safety outcomes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile/parameters: Area under the plasma concentration versus time curve (AUC) through Day 29</measure>
    <time_frame>Through Day 75</time_frame>
    <description>PK:AUC D0-D29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile/parameters: Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Through Day 75</time_frame>
    <description>PK: AUC D0-∞</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile/parameters: Maximum observed plasma concentration</measure>
    <time_frame>Through Day 75</time_frame>
    <description>PK: Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile/parameters: Time at which maximum plasma concentration occurs</measure>
    <time_frame>Through Day 75</time_frame>
    <description>PK: tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile/parameters: terminal elimination phase half life</measure>
    <time_frame>Through Day 75</time_frame>
    <description>PK: t(1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile/parameters: total clearance</measure>
    <time_frame>Through Day 75</time_frame>
    <description>PK: CL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile/parameters: volume of distribution</measure>
    <time_frame>Through Day 75</time_frame>
    <description>PK: Vd</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile/parameters: Extent of CSF distribution as estimated by TB006 CSF concentrations</measure>
    <time_frame>Through Day 75</time_frame>
    <description>PK: CSF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Through Day 75</time_frame>
    <description>Number of subjects and rate of treatment-emergent adverse events, graded by CTCAE Version 5.0, by dose group and all active treatment vs. placebo in non-Chinese healthy and Chinese healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-TB006 antibodies</measure>
    <time_frame>Through Day 75</time_frame>
    <description>Number and rate of subjects who develop anti-TB006 antibodies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>TB006 70 mg - 5000 mg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TB006 infused intravenously over 1 hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% normal saline infused intravenously over 1 hour</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TB006</intervention_name>
    <description>TB006</description>
    <arm_group_label>TB006 70 mg - 5000 mg IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sterile saline (Placebo)</intervention_name>
    <description>Sterile saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers, male or female 18-55 at the time of informed consent&#xD;
&#xD;
          -  In good health as determined by the principal investigator&#xD;
&#xD;
          -  Body weight of ≥ 50 kg and BMI within the range 18-30 kg/m2 (inclusive).&#xD;
&#xD;
          -  Chinese subjects are eligible to be included in the study if all of the following&#xD;
             criteria apply in addition to the above: Must have been born in China, with 2 Chinese&#xD;
             biological parents and 4 Chinese grandparents as confirmed by interview; Must have&#xD;
             lived no more than 10 years outside of China; Must not have changed their lifestyle or&#xD;
             habits significantly, including diet, since leaving China.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any current history of clinically significant disease in the opinion of the&#xD;
             investigator or receiving maintenance medications on a daily basis.&#xD;
&#xD;
          -  Any active or unstable clinically significant medical or psychiatric condition as&#xD;
             judged by the investigator.&#xD;
&#xD;
          -  Smokes cigarettes or uses other nicotine-containing products (eg, snuff, nicotine&#xD;
             patch, nicotine chewing gum, mock cigarettes, or inhalers), and has done so in the 3&#xD;
             months prior to screening.&#xD;
&#xD;
          -  Regular alcohol consumption within 6 months prior to the study defined as: an average&#xD;
             weekly intake of &gt; 20 units for males or &gt; 16 units for females. One unit is&#xD;
             equivalent to 8 glasses of alcohol: a half pint (∼240 mL) of beer, 1 glass (125 mL) of&#xD;
             wine or 1 (25 mL) measure of spirits.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Haig, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>TrueBinding, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Walling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Collaborative Neuroscience Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Cabral</last_name>
    <phone>714-891-0971</phone>
    <email>annecabral@cnstrial.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Collaborative Neuroscience Research, LLC (CNS)</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Cabral</last_name>
    </contact>
    <contact_backup>
      <last_name>David Walling, PhD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2021</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

